#01801.HK — FinScans

Release 📈 Stocks

Innovent Biologics Adds 7 Drugs to China's 2026 National Reimbursement List

November 14, 2026 (just now)

Innovent Biologics secures NRDL inclusion for seven innovative products effective January 1, 2027, expanding its reimbursed lineup to 17 drugs and enhancing…

01801.HK LLY

🌍 CN Read More →

Release 📈 Stocks

Innovent Biologics Subsidiary Altruist Gains NMPA Approval for NDA Filing

October 29, 2026 (15 days ago)

Innovent Biologics subsidiary Altruist Biologics receives NMPA acceptance for a new drug application, validating its localized manufacturing platform and CDMO operational strategy.

01801.HK

🌍 ASIA Read More →

Release 📈 Stocks

Innovent Biologics Gains NMPA Nod for Sintilimab in Advanced Melanoma

October 26, 2026 (18 days ago)

Innovent Biologics advances its oncology pipeline as the NMPA accepts a new indication application for sintilimab to treat advanced melanoma, signaling potential…

01801.HK

🌍 ASIA Read More →

Release 📈 Stocks

Innovent Biologics Presents Phase 1 Data for IBI3001 at ESMO Congress

October 25, 2026 (19 days ago)

Innovent Biologics shares Phase 1 clinical trial results for IBI3001 at the ESMO congress, marking a key milestone in the company's oncology…

01801.HK

🌍 ASIA Read More →

Release 📈 Stocks

Innovent Biologics Phase 3 Trial Hits Primary Endpoints for Gastric Cancer

October 23, 2026 (21 days ago)

Innovent Biologics' G-HOPE-001 trial confirms clinical efficacy for its ADC candidate, marking a major milestone for the company's oncology pipeline and potential…

01801.HK

🌍 ASIA Read More →

Release 📈 Stocks

Innovent Biologics Expands Phase 3 MarsLight-11 Study for NSCLC Treatment

September 28, 2026 (47 days ago)

Innovent Biologics broadens the scope of its Phase 3 MarsLight-11 study, targeting a wider patient population for its IBI363/TAK-928 oncology candidate to…

01801.HK

🌍 ASIA Read More →